Oxomemazina [INN-Spanish] en es it fr

Oxomemazina [INN-Spanish] Brand names, Oxomemazina [INN-Spanish] Analogs

Oxomemazina [INN-Spanish] Brand Names Mixture

  • Vanectyl-P Tablets (Prednisolone + Trimeprazine Tartrate)

Oxomemazina [INN-Spanish] Chemical_Formula


Oxomemazina [INN-Spanish] RX_link

No information avaliable

Oxomemazina [INN-Spanish] fda sheet

Oxomemazina [INN-Spanish] msds (material safety sheet)

Oxomemazina [INN-Spanish] Synthesis Reference

No information avaliable

Oxomemazina [INN-Spanish] Molecular Weight

298.447 g/mol

Oxomemazina [INN-Spanish] Melting Point

68 oC

Oxomemazina [INN-Spanish] H2O Solubility

0.942 mg/L

Oxomemazina [INN-Spanish] State


Oxomemazina [INN-Spanish] LogP


Oxomemazina [INN-Spanish] Dosage Forms

Tablet (2.5 mg); Syrup (2.5 mg/5mL); Capsule(5 mg)

Oxomemazina [INN-Spanish] Indication

Used to prevent and relieve allergic conditions which cause pruritus (itching) and urticaria (some allergic skin reactions).

Oxomemazina [INN-Spanish] Pharmacology

Trimeprazine (also known as Alimemazine) is a tricyclic antihistamine, similar in structure to the phenothiazine antipsychotics, but differing in the ring-substitution and chain characteristics. Trimeprazine is in the same class of drugs as chlorpromazine (Thorazine) and trifluoperazine (Stelazine); however, unlike the other drugs in this class, trimeprazine is not used clinically as an anti-psychotic. It acts as an anti-histamine, a sedative, and an anti-emetic (anti-nausea). Trimeprazine is used principally as an anti-emetic, to prevent motion sickness or as an anti-histamine in combination with other medications in cough and cold preparations. Tricyclic antihistamines are also structurally-related to the tricyclic antidepressants, explaining the antihistaminergic adverse effects of these two drug classes and also the poor tolerability profile of tricyclic H1-antihistamines.

Oxomemazina [INN-Spanish] Absorption

Well absorbed in the digestive tract.

Oxomemazina [INN-Spanish] side effects and Toxicity

Symptoms of overdose clumsiness or unsteadiness, seizures, severe drowsiness, flushing or redness of face, hallucinations, muscle spasms (especially of neck and back), restlessness, shortness of breath, shuffling walk, tic-like (jerky) movements of head and face, trembling and shaking of hands, and insomnia.

Oxomemazina [INN-Spanish] Patient Information

Prescriber should notify the patient to report an form of confusion, sedation, or hypotension. Inform the patient to avoid driving and other hazardous activity if drowsiness occurs. Also inform the patient to avoid alcohol and other CNS depressants while on trimeprazine.

Oxomemazina [INN-Spanish] Organisms Affected

Humans and other mammals